ACP-104
082004-051
Phase 2 small_molecule completed
Quick answer
ACP-104 for Schizophrenia is a Phase 2 program (small_molecule) at Acadia Pharmaceuticals B.V. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Acadia Pharmaceuticals B.V.
- Indication
- Schizophrenia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed